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Case Report 
Abstract 
 
Background: Investigation of glucose variability is crucial for patient with Type 1 Diabetes mellitus 
(T1DM) on insulin treatment. For Continuous Glucose Monitoring (CGM), FreeStyle Libre (Abbott) 
has been introduced to clinical practice with useful and beneficial efficacy.  
 
Case and Results: The patient was 55 year-old T1DM female with body mass index (BMI) 21 
kg/m
2
, HbA1c 8.0 %. She was on CGM for 14 days, with obtained glucose data in every 15 minutes. 
Treatment included multiple daily insulin injection (MDI) of Insulin Aspart 3 times and Insulin Glargin 
once a day. She showed unstable blood glucose variability with hyperglycemia and hypoglycemia, 
besides 2 hours delay shift in daily lifestyle rhythm. There was a discrepancy of HbA1c between 
actual value 8.0% and presumed value 6.9% by FreeStyle Libre. 
 
    Discussion and Conclusion: Obtained glucose data from FreeStyle Libre have been satisfactory. 
One reason for lower HbA1c value would be from the characteristic tendency in lower glucose region. 
Larger distribution of glucose variability would be due to delayed shift of lifestyle, sleep situation and 
irregular meal. These results would become the basal data for CGM, the reference to better 
modification of MDI and clinical diabetic practice in future research. 
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Case Report 
Introduction  
     Globally, patients with diabetes mellitus have 
been increasing in many countries [1]. Several 
mega study showed the importance of controlling 
the blood glucose such as Diabetes Control and 
Complications Trial (DCCT) and Epidemiology of 
Diabetes Interventions and Complications (EDIC) 
[2,3]. Then, study of the profile of blood glucose 
has been crucial. Authors and colleagues have 
continued research about daily profile of glucose, 
Morbus (M) value and low carbohydrate diet 
(LCD) in various patients and situations [4,5,6]. 
 
   On the other hand, some beneficial effect has 
been found in recent years that patients with 
T1DM show the tendency to live longer [7]. One 
of the reasons seems to be decreased episodes 
of hypoglycemia [8], and it was supported by the 
medical apparatus of continuous glucose 
monitoring (CGM) [9].  
 
CGM has been effective for decrease the 
episode of hypoglycemia. The DIAMOND study 
(Multiple Daily Injections and Continuous Glucose 
Monitoring in Diabetes) which was T1DM patients 
treated with multiple injection therapy, showed 
improved HbA1c with less hypoglycemia [10]. 
This study was a prospective, randomized clinical 
trial of CGM for adults. 
 
    CGM has been developed for the beneficial 
therapy of diabetes mellitus, especially for T1DM. 
At first, the concept of CGM was reported 
formerly by Updike et al. [11]. After that, there 
was improvement of electrodes for converting 
blood glucose concentration into electric signals, 
and several trials for CGM were found [12]. 
 
Recently, the guideline for CGM was presented 
by the Clinical and Laboratory Standards Institute 
(CLSI) [13]. In succession, there have been many 
research about the international standardization, 
including precision absolute relative difference 
(PARD) and mean absolute relative deviation 
(MARD) [14,15]. 
 
In recent years, useful medical apparatus, 
FreeStyle Libre (Abbott, USA) has been 
introduced to clinical practice. It has flash 
glucose-sensing technology and has been rather 
prevalent [9,16]. In this study, patient with T1DM 
is presented with some clinical problems to be 
explored in detail. 
 
Case Presentation 
History of present illness: The subject is a 
female patient with type 1 diabetes mellitus 
(T1DM). She is 55 year-old treated with insulin 
therapy for 12 years. The diabetic control was 
formerly stable, but it is rather unstable with 
HbA1c around 8% during half-year. There are 
episodes of hyperglycemia and hypoglycemia 
ranging from about 40 mg/dl to 400 mg/dl. 
 
    From mentioned above, we thought the 
necessity of further evaluation about swinging 
blood glucose. Then, daily profile of blood 
glucose was measured by the useful apparatus, 
FreeStyle Libre (Abbott). 
 
Physicals and Routine Exams: As basal data, 
her physicals were normal, such as vitals, heart, 
lung, abdomen and neurological findings. Her 
body mass index (BMI) was 21 kg/m
2
. 
Laboratory examination on routine revealed as 
follows: HbA1c 8.0%, glucose 356 mg/dl, Hb 
13.8 g/dl, WBC 6400 /μl, Plt 27.5 x 10
4
/μl, AST 
20 IU/ml, ALT 23 IU/ml, r-GT 27 IU/ml, Alb 4.4 
mg/dl, BUN 18 mg/dl, Cre 0.6mg/dl, Uric Acid 5.8 
mg/dl, HDL 39 mg/dl, LDL 94 mg/dl, TG 373 
mg/dl. HbA1c level was 7.4%-7.7% 6-9 months 
ago, and has been from 7.7% to 8.3% in last 6 
months, which indicates keeping rather high 
HbA1c value. 
  
   Insulin therapy: Patient has been on the 
multiple daily insulin injection (MDI) by Novo 
rapid (Novo Nordisk) 3 times a day, and Insulin 
Glargine (Eli Lilly and Company) at night once a 
day. The former is Insulin Aspart provided by 
pre–filled pen including 100 units/ml, and the 
latter is Insulin Glargine by BS injection kit FFP 
including 300 units/ml. As to the clock time and 
insulin units are in the following: Aspart is given 
21, 25, 23 units on 1000h, 1400h, 2000h and 
Glargine is given 11 units on 2400h. 
 
CGM study: The patient had CGM in May 
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FreeStyle Libre was 6.9%. On the other hand, 
HbA1c value in the outclinic at the first day of 
CGM study was 8.0%. There exist some 
discrepancies between the both values. 
 
Sensor-based device for CGM 
   The FreeStyle Libre Flash Glucose Monitoring 
system is the sensor-based device for blood 
glucose monitoring, which was produced by 
2018. Daily profile of blood glucose was 
measured by FreeStyle Libre, and it was 
satisfactory without any symptoms or problems. 
 
The results for 14 days are shown in Fig.1. 
Lifestyle of the patient seems to be about 2 hours 
delayed from usual lifestyle. The meal time is 
1000h, 1400h, 2000h, 3 times per day. Then, the 
injection of insulin is given at 1000h, 1400h, 
2000h, 2400h, 4 times per day. Median glucose 
showed rather high between 1000h and 1400h. 
Otherwise, median glucose level seems to be 
stable. 
 
From the result of Fig.1, there are two points to 
be investigated. One is unstable variability of 
glucose. The distribution of blood glucose was so 
wide associated with hyperglycemia and 
hypoglycemia. The patient did not feel specific 
symptoms, in both episodes of hyperglycemia 
and hypoglycemia. 
 
Another point is the discrepancy of HbA1c 
value. Presumed HbA1c value analyzed by 
Case Report 
application of CGM becomes wider for the 
patients with various situations [20]. Moreover, 
in United States, Food and Drug Administration 
(FDA) could approve the management decisions 
in 2016 including the insulin dosing from 
obtained CGM values [21]. 
     FreeStyle Libre was analyzed for safety, 
accuracy and user acceptability using 89 T1DM 
children cases [16]. On the other hand, 
Abbott Diabetes Care Inc.,Alameda,CA,USA [9]. 
      
   This newly-developed system was the first 
commercially available medical apparatus [17]. 
Its beneficial point would be that factory-
calibrated sensors are used [18]. When 
detecting for episodes of hyperglycemia and 
hypoglycemia, it can operate for replacing blood 
glucose examining and checking up trends and 
tracking patterns. The beneficial points are 
precise, convenient and small size for clinical 
practice [16]. The sensor is attached on the back 
of the arm for 2 weeks and automatically stores 
the data of glucose level in every 15 min [9,16]. 
Discussion 
     The research for CGM has been continued 
for years in order to develop the standard care 
for T1DM patients [19]. In comparison with the 
former blood glucose monitoring (BGM), newly-
developed CGM can represent 24-hour detail 
glycemic variability and prediction of changes on 
glucose at the same time. In succession, the 
 
Fig.1 Results of Continuous glucose monitoring (CGM) 
    CGM data for 14 days was obtained in May, 2018. Presumed HbA1c was 6.9% from analysis of FreeStyle 
Libre. On the other hand, actual HbA1c value in outclinic on the first day of this exam was 8.0%. There was a 
discrepancy of HbA1c value between them. 
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FreeStyle Libre subcutaneous continuous 
glucose monitoring system (SC-CGM) showed 
the data that Mean difference (SD) was reported 
to be -43.4 (20) mg/dl [22]. In addition, there was 
tendency to indicate lower measured values in 
the lower ranges, and was also underestimation 
of the response of glucose rise for the meal 
loading [23]. It is reported that the mean 
absolute relative difference (MARD) of glucose 
levels would be 20.3%, 14.7%, 9.6% in the 
range of <72, 72-180, 181<, respectively [24]. 
   These data reported before may be one of the 
reasons for explaining the lower value in HbA1c 
of our current study. 
 
In this study, blood glucose variability of the 
T1DM case was investigated by CGM. Blood 
glucose profile for 14 days showed rather wider 
range of fluctuations, compared with usual and 
standard case. There was characteristic situation 
in this case with insulin treatment. Time lag and 
delay was found in the daily life of the patient. 
About 2 hours delay was present in the clock 
time of meal and insulin injection just before 
meal. As comparing the usual time with that in 
this case, it is 08h to 10h in the morning, 12h to 
14h in the day, 18h to 20h in the evening and 
22h to 24h before going to bed. 
 
    From midnight to early morning, a wide 
distribution of blood sugar is observed from 0200 
h to 0800h. As to this phenomenon, several 
factors are involved in the cause. Hypoglycemia 
occasionally continues from midnight to early 
morning. In this situation, the patient has not 
taken anything before going to bed. Although 
blood glucose level is rather low, she is sleeping 
fast without recognizing hypoglycemic symptoms 
or any other symptoms. As to well-known 
hypoglycemic symptoms, she did not feel 
hunger, palpitations, sweating, tremor, fatigue, 
headache, dizziness, drowsiness and so on. 
    Conversely in 5 out of 14 days, hyperglycemia 
was continuing from midnight to early morning. 
One cause would be the following episode. 
When she was just preparing the injection of 
Lantus on the table, she was falling to sleep at 
once sitting on the chair. Another episode is 
found that she took milk and bread during lying 
Case Report 
in the bed because of feeling hungry. In this 
case, blood glucose increased about 180 mg/dL. 
Intake amount of carbohydrate seemed to be 35-
40 g. It is said that blood glucose increases 
5mg/dL for carbohydrate 1g in T1DM, and then it 
seems to be consistent with the actual increase. 
 
In every morning at 10 am, blood sugar always 
converges to the same level. Breakfast is always 
vegetable salad such as tomato and cabbage, 
and bread. There is a small fluctuation of blood 
glucose during 10-14h. This is probable from the 
different physical activity, such as housework, 
washing and walking around. 
 
   The afternoon meal is usually at 14 o'clock. 
The way to eat is vegetable first, and there are 
many dishes such as cabbage and fish at lunch, 
while carbohydrate is rare or less. At 15-20 
o'clock, she always has lots of things to do 
associate with physical activity and exercise. As 
the exercise is harder, blood glucose is lower at 
night. For dinner, she takes vegetables, meat, 
fish, egg and rice about 80g including 28g of 
carbohydrate. 
 
    According to the recent report, there were 
studies about the accuracy of blood glucose 
monitors (BGMs). The results were that only 6 of 
18 commercially available BGMs consistently met 
accuracy standards. Consequently, the necessity 
for CGM study would be increased with 
expectation from now [25]. 
Conclusion 
    As regard to this study, glucose variability in 
T1DM case was investigated by the application of 
CGM using FreeStyle Libre. Because the case 
has delayed lifestyle rhythm, it is so beneficial 
and effective for better diabetic control. These 
obtained results would become fundamental data 
for clinical practice and future study in diabetic 
practice. 
Supplement 
    This study was conducted in compliance with  
the ethical principles of the Declaration of 
Helsinki. Furthermore, it was conducted with 
Japan’s Act on the Protection of Personal 
Information along  with  the  Ministerial Ordinance 
on  Good  Clinical  Practice  (GCP)  for  Drug  
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(Ordinance of Ministry of Health and Welfare 
No. 28 of March 27, 1997). Ethical committee 
meeting was held including physicians, nurse, 
pharmacist, clinical engineer and academic 
experts. Informed consent and written consent 
were obtained from the subject. 
 
 The authors would like to thank the patient and 
staffs for their cooperation and support. The 
authors declare that they have no conflicts of 
interest. 
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